Home Cart Sign in  
Chemical Structure| 73590-58-6 Chemical Structure| 73590-58-6

Structure of Omeprazole
CAS No.: 73590-58-6

Chemical Structure| 73590-58-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Omeprazole is an inhibitor of proton pump with IC50 of 1.1 μM which can be used to treat dyspepsia.

Synonyms: H 16868; OMEP; OMZ

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Omeprazole

CAS No. :73590-58-6
Formula : C17H19N3O3S
M.W : 345.42
SMILES Code : O=S(C1=NC2=CC=C(OC)C=C2N1)CC3=NC=C(C)C(OC)=C3C
Synonyms :
H 16868; OMEP; OMZ
MDL No. :MFCD00083192
InChI Key :SUBDBMMJDZJVOS-UHFFFAOYSA-N
Pubchem ID :4594

Safety of Omeprazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P264-P280-P302+P352-P312-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

Description
Omeprazole (H 16868), a proton pump inhibitor (PPI), is employed in managing acid-related gastrointestinal conditions. It exhibits competitive inhibition of the CYP2C19 enzyme with a Ki ranging between 2 and 6 μM[1].
Target
  • Proton Pump

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04170270 Bleeding Peptic Ulcer EARLY_PHASE1 UNKNOWN 2025-01-21 -
NCT04930991 Exocrine Pancreatic Cancer EARLY_PHASE1 RECRUITING 2025-06-26 Stephenson Cancer Center, Okla... More >>homa City, Oklahoma, 73104, United States Less <<
NCT01045434 Healthy PHASE1 COMPLETED 2025-03-07 Wellquest Clinical Research, M... More >>umbai, Maharashtra, 400 013, India Less <<
NCT01777854 Laryngopharyngeal Reflux|Throa... More >>t Pain Less << PHASE4 TERMINATED 2025-07-15 Genesys Regional Medical Cente... More >>r, Grand Blanc, Michigan, 48439, United States Less <<
NCT01458990 Cirrhosis|Healthy COMPLETED 2025-02-18 Hunter Holmes McGuire VA Medic... More >>al Center, Richmond, Virginia, 23249, United States Less <<
NCT03980496 Non-variceal Upper Gastrointes... More >>tinal Bleeding Less << PHASE4 COMPLETED 2013-06-08 Department of Gastroenterology... More >> and Internal Medicine, Medical University of Bialystok, Bia?ystok, Podlaskie, 15-276, Poland Less <<
NCT00519519 Bleeding Peptic Ulcers Disease PHASE3 COMPLETED 2025-11-07 Department of Surgery, Singapo... More >>re General Hospital, Outram Road, Singapore, Outram road, 169608, Singapore|Singapore General Hospital, Outram Road, Singapore, Outram Road, 169608, Singapore|Department of Surgery, Singapore General Hospital, Singapore, Outram road, 169608, Singapore|Singapore General Hospital, Singapore, Outram Road, 169608, Singapore Less <<
NCT01824199 Esophagitis EARLY_PHASE1 WITHDRAWN 2025-11-16 Mayo Clinic in Rochester, Roch... More >>ester, Minnesota, 55905, United States Less <<
NCT02595372 Cancer of the Breast PHASE2 COMPLETED 2021-03-01 Georgetown University, Washing... More >>ton, District of Columbia, 20007, United States|Washington Hospital, Washington, District of Columbia, 20010, United States|Indiana University Health North Hospital, Carmel, Indiana, 46032, United States|Indiana University Health Hospital, Indianapolis, Indiana, 46202, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Spring Mill Medical Center, Indianapolis, Indiana, 46290, United States|Franklin Square Medical Center, Baltimore, Maryland, 21237, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, United States|Ohio State University, Columbus, Ohio, 43210, United States Less <<
NCT00164866 Peptic Ulcer PHASE4 COMPLETED 2025-09-05 Endoscopy Center, Prince of Wa... More >>les Hospital, Hong Kong SAR, China Less <<
NCT01921920 Bioequivalence, AUC, Cmax, Pha... More >>rmacokinetics Less << PHASE1 COMPLETED 2025-11-13 Research Site, Overland Park, ... More >>Kansas, United States Less <<
NCT00259077 Non-erosive Reflux Disease PHASE3 COMPLETED 2025-07-04 Asa, Japan|Beppu, Japan|Chiyod... More >>a, Japan|Fujieda, Japan|Fukuoka, Japan|Kanagawa, Japan|Kawagucki, Japan|Kitakyushu, Japan|Kita, Japan|Kyota, Japan|Meguro, Japan|Minato, Japan|Mitsukaido, Japan|Mizumaki, Japan|Nagoya, Japan|Nanao, Japan|Onoda, Japan|Osaka, Japan|Ota, Japan|Otsu, Japan|Sapporo, Japan|Shinagawa, Japan|Shinjuku, Japan|Tokyo, Japan|Ube, Japan|Yukuhashi, Japan Less <<
NCT01045642 Healthy PHASE1 COMPLETED 2025-03-07 Vimta Labs Limited, Hyderabad,... More >> Andhra Pradesh, 500 051, India Less <<
NCT02844621 Healthy Volunteers EARLY_PHASE1 COMPLETED 2025-12-16 First Outpatient Research Unit... More >>, Medical Arts and Research Center, San Antonio, Texas, 78229, United States Less <<
NCT02893709 Gastroesophageal Reflux Diseas... More >>e Less << COMPLETED 2025-07-16 Changi General Hospital, Singa... More >>pore, 529889, Singapore Less <<
NCT00582972 Osteoporosis|Achlorhydria|GERD... More >>|Hip Fracture Less << PHASE4 COMPLETED 2025-12-10 University of Wisconsin Hospit... More >>al and Clinics, Madison, Wisconsin, 53792, United States Less <<
NCT01657578 Gastroesophageal Reflux Diseas... More >>e (GERD) Less << PHASE2 COMPLETED 2025-02-12 Hospital Robert Debre, Paris, ... More >>75019, France Less <<
NCT05680870 Chemotherapy Induced Periphera... More >>l Neuropathy Less << PHASE3 UNKNOWN 2025-12-23 -
NCT00256737 GERD PHASE3 COMPLETED 2025-10-05 Research Site, Aalborg, Denmar... More >>k|Research Site, Glostrup, Denmark|Research Site, Hiller?d, Denmark|Research Site, Kolding, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Kuopio, Finland|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Research Site, Trondheim, Norway|Research Site, G?teborg, Sweden|Research Site, Stockholm, Sweden|Research Site, ?rebro, Sweden Less <<
NCT00259051 Non-erosive Reflux Disease PHASE3 COMPLETED 2025-08-04 Research Site, Ashahikawa, Jap... More >>an|Research Site, Fukuoka, Japan|Research Site, Hiroshima, Japan|Research Site, Ichihara, Japan|Research Site, Kochi, Japan|Research Site, Koshigaya, Japan|Research Site, Kurashiki, Japan|Research Site, Nakano, Japan|Research Site, Nerima-ku, Japan|Research Site, Oita, Japan|Research Site, Osaka, Japan|Research Site, Sapporo, Japan|Research Site, Yamato, Japan Less <<
NCT02299687 Stomach Ulcer PHASE1 COMPLETED - Seoul National University Hosp... More >>ital, Seoul, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.90mL

0.58mL

0.29mL

14.48mL

2.90mL

1.45mL

28.95mL

5.79mL

2.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories